NCT02271906View on ClinicalTrials.gov

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

August 16, 2017

Study Completion Date

August 16, 2017

Conditions
Lung Cancer
Interventions
DRUG

BIBW 2992

40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER